Akili, Inc.

Equities

AKLI

US00974B1070

Advanced Medical Equipment & Technology

End-of-day quote Nasdaq Other stock markets 18:00:00 2024-05-12 EDT			5-day change	1st Jan Change
0.4384 ^USD	+2.62%		+3.89%	-10.00%

04-30	Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	CI
04-30	Akili, Inc. to Reduce Workforce	CI

Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 29, 2024 at 04:09 pm

Akili, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 0.749 million compared to USD 0.111 million a year ago. Net loss was USD 11.15 million compared to USD 16.82 million a year ago.

Latest news about Akili, Inc.

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	04-30	CI
Akili, Inc. to Reduce Workforce	04-30	CI
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	04-30	CI
Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-29	CI
Earnings Flash (AKLI) AKILI Posts Q4 Revenue $749,000, vs. Street Est of $0.78M	02-29	MT
Sector Update: Health Care Stocks Ease Late Afternoon	02-26	MT
Akili Shares More Than Double After Submission of ADHD Treatment for Marketing Approval in Japan	02-26	MT
Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan	02-26	DJ
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan	02-26	CI
Akili Appoints John Spinale to the Board and Audit Committee	02-21	CI
Akili, Inc. Announces Executive Changes, Effective on January 12, 2024	01-05	CI
Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024	01-05	CI
Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board	12-20	CI
Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration	12-18	CI
Transcript : Akili, Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
Earnings Flash (AKLI) AKILI Reports Q3 Revenue $702,000	11-09	MT
Akili, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Top Premarket Decliners	23-10-26	MT
Akili, Inc. Releases Results from A New Study Examining the Way in Which Adhd Impacting the U.S. Workforce	23-10-12	CI
Akili Names Matt Franklin as Chief Executive, Eddie Martucci as Board Chair	23-10-06	MT
Akili, Inc. Announces Executive Changes	23-10-06	CI
Akili, Inc. Announces CEO Changes	23-10-06	CI
Akili Releases EndeavorOTC on Android Devices, Expanding Treatment Access for Millions of Adults with Adhd	23-09-21	CI
Transcript : Akili, Inc. - Special Call	23-09-14

Chart Akili, Inc.

Duration

Period

More charts

Company Profile

Akili, Inc. is a digital medicine company engaged in the development of cognitive treatments through technologies. The Companyâs approach of developing and commercializing technologies is designed to directly target the physiology of the brain. Its therapeutic engines are designed to target cognitive functions with the potential to address multiple medical conditions presenting the same functional cognitive impairments. Its product, EndeavorRx, is indicated for use to improve attention function for children ages 8-17 with primarily inattentive or combined-type attention-deficit/hyperactivity disorder (ADHD), who have a demonstrated attention issue. Its product, EndeavorOTC, which is built on the same platform as EndeavorRx, nationwide without a prescription to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined type ADHD. In addition, the Company has several investigator-initiated studies.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-13 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Akili, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4384 USD

Average target price

0.65 USD

Spread / Average Target

+48.27%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
AKILI, INC.	-10.00%	34.46M
THERMO FISHER SCIENTIFIC	+11.29%	225B
DANAHER CORPORATION	+8.76%	186B
INTUITIVE SURGICAL, INC.	+12.90%	135B
BOSTON SCIENTIFIC CORPORATION	+25.95%	107B
SIEMENS HEALTHINEERS AG	+0.15%	63.56B
EDWARDS LIFESCIENCES CORPORATION	+11.08%	51.04B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+5.62%	51.32B
AGILENT TECHNOLOGIES, INC.	+6.28%	43.3B
GE HEALTHCARE TECHNOLOGIES INC.	+4.80%	36.99B

Other Advanced Medical Equipment & Technology